लोड हो रहा है...
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts
BACKGROUND: Poly-ADP ribose polymerase (PARP) inhibitor-based cancer therapy selectively targets cells with deficient homologous recombination repair. Considering their long-term use in maintenance treatment, any potential mutagenic effect of PARP inhibitor treatment could accelerate the development...
में बचाया:
| में प्रकाशित: | Br J Cancer |
|---|---|
| मुख्य लेखकों: | , , , , , , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Nature Publishing Group UK
2018
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6265254/ https://ncbi.nlm.nih.gov/pubmed/30425352 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0312-6 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|